Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Evommune to Host KOL Webinar on April 13, 2026 Highlighting the Potential of MRGPRX2 Inhibition in Migraine

businesswire.com
EVMN The article announces a webinar to discuss the potential of MRGPRX2 inhibition in migraine treatment. While the topic is relevant to Evommune's drug candidate EVO756, the announcement itself is informational and does not provide new data or performance indicators for the company.

Evommune to Host KOL Webinar on April 13, 2026 Highlighting the Potential of MRGPRX2 Inhibition in Migraine PALO ALTO, Calif. & NEW YORK--( BUSINESS WIRE)--Evommune, Inc. (NYSE: EVMN) (“Evommune” or the “Company”), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced it will host a webinar highlighting the migraine treatment landscape and the role of MRGPRX2 inhibition on this debilitating condition on Monday, April 13, 2026, at 11:00 a.m. PT (2:00 p.m. ET).

The event will include presentations from members of Evommune’s management team and the following two leading experts in migraine:

A live Q&A session will follow the formal presentations.

A webcast for the event can be accessed in the News & Events page of the Company’s IR webpage or by clicking here. The webcast will be archived on the same page for 90 days following the event.

About EVO756

EVO756 is a first-in-class, potent and highly selective oral small molecule antagonist of Mas-related G protein-coupled receptor X2 (MRGPRX2), a receptor predominantly found on mast cells and peripheral sensory neurons. Evommune seeks to produce the first MRGPRX2-targeted oral treatment for chronic inflammatory diseases, including Chronic Spontaneous Urticaria (CSU), atopic dermatitis (AD), and migraine, with additional possible indication expansions. Top-line data from a Phase 2b dose-ranging trial in moderate-to-severe CSU is expected in the second quarter of 2026 and moderate-to-severe AD in the second half of 2026.

About Evommune, Inc.

Evommune, Inc., is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases. The Company’s mission is to improve patients’ daily lives and prevent the long-term effects of uncontrolled inflammation that are a consequence of the limitations of existing therapies. To achieve this, Evommune is advancing a portfolio of differentiated product candidates that target key drivers of chronic inflammation. For more information, please visit www.evommune.com and follow us on LinkedIn.